The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase I Study of QL1604 for Advanced Solid Tumors
Official Title: A Phase I Clinical Study to Evaluate Safety、 Tolerability, and Pharmacokinetics of QL1604 for the Treatment of Advanced Solid Tumors - A Phase Ic Preliminary Efficacy Expansion Study
Study ID: NCT05801094
Brief Summary: In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The First Affliated Hospital of Nanchang University, Nanchang, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
Name: Weijian Guo, PhD
Affiliation: Fudan University
Role: STUDY_CHAIR
Name: Jianping Xiong, PhD
Affiliation: The First Affliated Hospital of Nanchang University
Role: STUDY_CHAIR